Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Chemotherapy still constitutes the backbone of small-cell lung cancer (SCLC) therapy,
particularly in the extensive disease (ED) stage (ED-SCLC). Despite the fact that a
substantial complete response rate could be achieved in SCLC patients receiving etoposide -
cisplatin doublet, cure remains the exception. Overall survival in patients receiving this
combination is 10 months and progression free survival 6.3 months. At time of progression two
options are hitherto accepted: reinduction of carboplatin - etoposide doublet or, for
patients unfit for reinduction, topotecan single-drug regimen. However, in both clinical
cases, median survival hardly achieves 33 weeks. Consistent data using anti - PDL1
(Programmed death-ligand 1) or anti PD1 (programmed cell death 1) antibodies suggest that
they are active as single drug regimens in many malignant diseases. Taking into account the
rich tumor infiltrating lymphocyte in pathological specimens of SCLC, we can hypothesize that
experimental use of ATEZOLIZUMAB (MPDL3280A) in patients is ethical pending that it
demonstrates activity in the second line setting.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique